Divi's Laboratories DIVISLAB
Global leader in generic APIs (naproxen, gabapentin, dextromethorphan and others) and custom synthesis for big pharma, including peptides and GLP-1 building blocks
Mapped in 1 theme: Pharmaceuticals.
Where Divi's Laboratories sits in the supply chain
Divi's Laboratories appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 7,845 | 9,360 | 10,560 |
| Net profit | 1,600 | 2,191 | 2,568 |
Latest-year revenue ₹10,560 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Custom synthesis grew 45% YoY in Q1 FY27 on dedicated big-pharma projects; EBITDA margin ~41%
- Large net-cash balance sheet and clean USFDA record
- Integrated peptide platform positioned for GLP-1 demand and BIOSECURE shifts
Risks
- Validation-batch revenue is lumpy - margin spike in Q1 FY27 may not repeat
- Valuation already prices in CDMO success
- Customer concentration in custom synthesis
Common questions
What does Divi's Laboratories do?
Global leader in generic APIs (naproxen, gabapentin, dextromethorphan and others) and custom synthesis for big pharma, including peptides and GLP-1 building blocks.
Where does Divi's Laboratories sit in the supply chain?
Divi's Laboratories (NSE: DIVISLAB) is mapped in 2 supply-chain layers: APIs (active ingredients) (Pharmaceuticals) and CDMO & contract research (Pharmaceuticals).
Who are Divi's Laboratories' peers?
In the APIs (active ingredients) layer of Pharmaceuticals: Laurus Labs, Aarti Drugs, Solara Active Pharma Sciences, Concord Biotech, Granules India, Neuland Laboratories and 2 more.
What is Divi's Laboratories' market cap and valuation?
As of 30 Oct 2026: market cap ₹2.60L Cr, P/E 87.2x, ROCE 22.0%, ROE 16.5%, dividend yield 0.31%.